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Epidermolysis bullosa acquisita (EBA) is a chronic acquired 
blistering disease with characteristic clinical, pathologic, and 
immunopathologic features. The disease is characterized im-
munopathologically by circulating and tissue-bound IgG 
class autoantibodies (EBA antibodies) to the basement mem-
brane zone of stratified squamous epithelium. Previous stud-
ies have shown that circulating and tissue-bound EBA anti-
bodies are heterogenous in · their ability to activate 
complement and have raised the possibility that functional 
heterogeneity might be related to IgG subclass restriction. In 
E pidermolysis bullosa acquisita (EBA) is an uncommon, chronic, acquired subepidermal blistering disease char-acterized by circulating and tissue-bound autoantibodies to the basement membrane zone (BMZ) of stratified squamous epithelium. The antibodies belong mainly to 
rhe IgG class, bind on and just beneath the lamina densa, and react 
with type VII collagen, a matrix protein specific for basement mem-
branes of stratified squamous epithelia. 
Complement binding immunofluorescent studies have shown 
that circulating EBA antibodies consist of both complement bind-
ing and non-complement binding populations (2]. Evidence that 
tissue-bound EBA antibodies are also functionally heterogenous has 
been obtained from recent studies indicating that BMZ immune 
deposi ts in some EBA patients can activate complement and gener-
ate complement-derived mediators of inflammation, whereas in 
others they cannot (3]. One factor that could contribute to heteroge-
neity in the ability to activate complement is the subclass distribu-
tion of IgG EBA antibodies. Some subclasses, such as IgG1 and 
lgG3, are potent complement activators, whereas IgG2 and espe-
cially IgG4 are weak activators (4,5]. 
To address this question, we have characterized the IgG sub-
classes of both circulating and tissue-bound EBA antibodies and 
have examined the relationship between subclass distribution and 
the abi lity of the antibodies to bind complement at the BMZ. In 
addition, we have characterized other classes of circulating and tis-
sue-bound EBA antibodies. 
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this study, we have characterized the IgG subclasses of the 
circulating and tissue-bound EBA antibodies by immunofluo-
rescence and have examined the relationship between IgG 
subclass and complement binding. The results show that 
EBA antibodies belonging to all IgG subclasses are present in 
the skin of EBA patients. The results also show that EBA 
antibodies belonging to all IgG subclasses are present in the 
sera of most patients, including sera with and without com-
plement binding EBA antibodies.] Invest Dermato/95:317-
319, 1990 
MATERIALS AND METHODS 
Tissue and Sera Perilesional skin (3-4 mm punch biopsies) and 
sera were obtained from 10 EBA patients, and sera were obtained 
from an additional 13 patients. In all patients, EBA was diagnosed 
on the basis of previously published criteria (2]. Sera were aliquoted 
and stored at -70oC until used. Biopsies were quick-frozen in 
liquid N2, mounted in OCT compound, and stored frozen at 
-70 o C. Normal human skin used for immunofluorescence was 
immediately frozen in liquid N2 or first separated through the 
lamina Iucida, as previously described (6], mounted in OCT com-
pound, and then frozen. All dilutions of sera were made in 0.01 M 
PBS. Fresh normal human serum was used as a source of comple-
ment. 
Antibodies The following fluorescein isothiocyanate-conju-
gated (FITC) goat antibodies to human proteins were used: i) affin-
ity purified anti-IgG (Cappel Labs, Cochranville, PA), ii) anti-IgD 
(heavy chain specific) (Cappel), iii) heavy chain specific anti-IgM 
(Kirkegaard & Perry, Gaithersburg, MD.), iv) heavy chain specific 
anti-IgA (Kirkegaard & Perry), v) anti-C3 (Cappel), vi) anti-lambda 
light chain (Cappel) , and vii) anti-kappa light chain (Atlantic Anti-
bodies, Scarborough, ME). The following murine monoclonal anti-
bodies were used: 1) anti-human IgE (Hybritech, San Diego, CA), 
2) IgG subclass specific antibodies for human IgG1, IgG2, IgG3, 
and IgG4 (Bionetics, Irving, TX), 3) IgA subclass specific antibodies 
for human IgA1 and IgA2 (gift from John F. Kearney, Ph.D., Uni-
versity of Alabama) (7]. FITC-conjugated sheep anti-mouse IgG 
antibody (species specific) was purchased from Cappel Labs. 
ELISA Enzyme-linked immunosorbent assays (ELISA) of human 
myeloma proteins and purified IgG subclasses were used to deter-
mine the specificity of goat antibodies to human kappa and lambda 
light chains and murine monoclonal antibodies to IgG subclasses, 
respectively. The antibodies showed no cross reactivity at the fol-
lowing dilutions: IgG 1 1: 5000; IgG2 1: 1500; IgG3 1: 2000; IgG4 
1 : 8000; anti-lambda 1 : 200; and anti-kappa 1 : 200. 
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Table I. Positive Staining of H eavy and Light Chains 
IgG lgA IgM IgD IgE K .l. 
Biopsies 10/10 2/10 5/10 2/10 5"/10 10/ 10 10/10 
Sera 21/23 0/21 3/21 0/21 ND• 18/19 18/19 
11 W eak positive staining. 
• ND, not done. 
Immunofluorescence A standard direct immunofluorescence 
procedure was used to charac terize IgG, IgA, IgD, kappa and 
lambda light chains, and C3 in EBA biopsies. N ormal human skin 
was used as a negative substrate control in these studies. A two-step 
techniq ue employing an initial unconjugated murine monoclonal 
antibody followed by a FITC-conjugated sheep antibody to murine 
IgG was used to characte rize IgE, !gA l, IgA2, IgG l, IgG2, IgG3, 
and IgG4 deposits in EBA biopsies and serum EBA antibodies . 
Serum antibodies were assayed with 1.0 M NaCl-separated normal 
human skin substrate as previously described (6]. Indirect C3-bind-
ing immunofluorescence was performed on NaCI-separated skin as 
previously described (8]. 
Slides were examined under a Leitz Orthoplan fluorescence mi-
croscope. Intensity of specific immunofluorescence w as graded on a 
scale of 0 (no staining) to 3 + (intense staining). Trace staining was 
indicated when the staining was barely discernible but specific. 
RESULTS 
Immunoreactants in EBA Biopsies 
Heav.y a11d Light Cha i11s: Perilesional skin specimens from 10 EBA 
patients were examined. All showed linear deposits of IgG at the 
BMZ. In addition, two specimens showed linear IgA, and another 
two, linear IgD deposits at the BMZ. Five biopsies had linear IgM at 
th e BMZ, whereas five stained weakly for IgE along the BMZ. Two 
of these biopsies were positive for both IgM and IgE. One of the 
patients with IgM deposits was rh eumatoid facror positive. In all 
cases staining for immunoglobulin classes other than l gG was less 
intense th an IgG stainin g. Linear deposits of kappa and lambda light 
chains were also seen in all biopsies, and we observed no difference 
in the staining intensity between these light chains (Table 1). 
St~bclasses : Linear deposits of IgG subclass antibodies were seen in 
al l EBA biopsies. Every biopsy contained at least two subclasses and 
most contained three or four subclasses. IgG 1 was present in 80% of 
biopsies, IgG2 in 100%, IgG3 in 70%, and IgG4 in 100% (Table II). 
Every biopsy contained IgG 1, IgG3 , or both. In the two biopsies 
Table II. Tiss ue Bou nd lgG Subclasses 
Patient IgG l lgG2 IgG3 lgG4 
1 1+ 2+ 1+ 2+ 
2 2+ tr" 
3 1+ 3 + 2+ 
4 1+ 2+ 1+ 3+ 
5 2+ 2+ tr 3+ 
6 1+ 2+ 3+ 2+ 
7 3+ 1+ 3+ 
8 1+ tr 1+ tr 
9 1+ 1+ tr 2 + 
10 1+ 2+ 3+ 
Perce nt positive 80% 100% 70% 100% 
~ tr , trace. 
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Table III . Comparison of IgG Subclass and C3 Binding in Sera 
Patient IgG l IgG2 IgG3 lgG4 C3 Binding Tirer 
1 1+ 2+ 2+ 3+ + 1: 20 
2 2+ 1+ 3+ 3+ + 1 :20 
3 tr tr 2+ 
4 1+ tr + N• 
5 tr 2+ tr 3+ 
6 1+ 2+ 1+ 3+ 
7 2 + 2+ 3+ + 1: 40 
8 tr 1+ 2+ + N 
9 tr 3+ 1+ 1+ + 1:10 
10 tr 2+ 2+ 
11 1+ tr tr + 1:5 
12 tr tr + 
13 1+ 2+ tr 2 + 
14 tr 2+ tr 3+ 
15 1+ tr tr 1+ + 1: 10 
16 tr 2+ 3+ 
17 tr 1+ tr 
18 tr tr 
Percent Positive 94 94 50 94 44 
'N, Nect or undiluted. 
with IgA deposits, both stained with antisera for lgA1 and one 
stained for IgA2. 
Compleme11t: 
biopsies . 
Linear deposits of C3 were present at the BMZ in all 
Circulating Antibodies 
Heavy and Light Chai11s: IgG.EBA antibodies were detected in 21 
of23 EBA sera indirect IgG immunofluorescence on 1.0 M NaCI-
separated skin. In addition, three of the sera had low titer lgM 
anti-BMZ antibodies that reacted with the substrate in a pattern 
indistinguishable from IgG EBA antibodies. One of these patients 
was rheumatoid factor positive. No other lg class anti-BMZ antibod-
ies were detected. Kappa and lambda light chain staining of approxi-
mately equal immunofluorescence intensity was observed at the 
BMZ in 18 of 19 sera tested. 
Subclasses: The IgG subclasses of circulatin g EBA antibodies were 
characterized in 23 sera . IgG 1 EBA antibody were present in 94% of 
those sera, IgG2 in 94%, IgG3 in 50%, and IgG4 in 94%. IgG 1. 
l gG2, or both were present in all but one serum. An analysis of rht 
prevalence of subclasses in corresponding sera and skin showed a 
75%-88% concordance. 
Complement Binding: Eight of 18 EBA sera were found to contain 
complement-binding EBA antibodies (Table III) . W e observed no 
significant correlation· between the IgG subclass distribution ofEBA 
antibodies and complement-binding. H owever, IgG 1 and IgG 
subclasses did appear to be more intensely staining in complement· 
binding compared to non - complement-binding sera. 
DISCUSSION 
The results of this study confirm previous reports th at circulating 
and tissue-bound EBA antibodies belong predominantly to the IgG 
class (2]. Evidence for EBA antibodies belonging to the IgA, IgM, 
and IgE classes has also been reported, and their presence was also 
confirmed in this study [9] . As in previous studies, we found that 
EBA antibodies belonging to cl asses other than IgG occur in t ht 
minority of patients. We also detected circulating IgM anti-BMZ 
antibod ies that bound to separated normal human skin in a pattern 
identical to IgG EBA antibodies in three sera. To our knowledge, 
this is th e first evidence of circulating EBA antibodies of a class other 
than IgG . 
Iri addition to Ig heavy chains, we examined for kappa and lambda 
light chains in EBA antibodies and found that both types Wert' 
present in all biopsies . This findin g supports the evidence obtained 
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from heavy chain analysis that EBA antibodies are polyclonal (3]. 
Our major objective in this study was to determine the IgG subclass 
distribution of EBA antibodies and examine the relationship of 
those subclasses and complement-binding EBA antibodies. Our re-
sults showed that both circulating and tissue-bound EBA antibodies 
in most patients contained multiple subclasses and that there is no 
clear relationship between complement deposition in vivo or circu-
lating complement-binding and IgG subclass distribution. For that 
reason we conclude that the variability in functional activity ofEBA 
antibodies is not due to IgG subclass distribution. These results are 
consistent with our view that variability in complement activation is 
more a function of amounts of complement activating subclasses 
than subclass distribution. 
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